Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations01:51

Vaccinations

Overview
Chickenpox01:20

Chickenpox

Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same author

Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].

Gynecologic oncology·2026
Same author

Endometriosis and ovarian cancer risk.

Gynecologic oncology·2026
Same author

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Gynecologic oncology·2026
Same author

Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends.

Gynecologic oncology·2026
Same author

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Lancet (London, England)·2026

Related Experiment Video

Updated: Jul 5, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Age considerations when vaccinating against HPV.

Thomas C Wright1, Warner K Huh, Bradley J Monk

  • 1Columbia University, New York, New York 10032, USA. tcw1@columbia.edu

Gynecologic Oncology
|June 14, 2008
PubMed
Summary
This summary is machine-generated.

Human papillomavirus (HPV) vaccines are highly effective and safe for preventing HPV-associated diseases. Recommendations for HPV vaccination consider age, sexual activity, and previous exposure, extending benefits beyond the primary target group.

Related Experiment Videos

Last Updated: Jul 5, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Area of Science:

  • Vaccinology
  • Public Health
  • Gynecology

Background:

  • Human papillomavirus (HPV) infections are a significant global health concern, leading to substantial morbidity and mortality, particularly cervical cancer.
  • Cervical cancer prevention is a priority, with prophylactic HPV vaccines offering a crucial public health intervention.
  • Understanding the interplay between age and HPV infection prevalence is essential for effective vaccination strategies.

Purpose of the Study:

  • To review the efficacy and safety of HPV vaccines.
  • To discuss the complex considerations for recommending HPV vaccination across different age groups.
  • To inform healthcare providers on optimizing HPV vaccine uptake to reduce HPV-associated disease burden.

Main Methods:

  • Literature review of HPV vaccine effectiveness and safety data.
  • Analysis of HPV infection prevalence by age and sexual activity.
  • Examination of current vaccination guidelines and recommendations.

Main Results:

  • HPV vaccines are demonstrated to be highly effective and safe.
  • Pre-adolescent females (11-12 years) are the primary target for HPV vaccination in the US.
  • Catch-up vaccination is recommended for females aged 13-26, with potential benefits for unvaccinated individuals over 26.

Conclusions:

  • HPV vaccination is a critical tool for preventing cervical cancer and other HPV-related diseases.
  • Vaccination recommendations should be tailored, considering individual risk factors and potential for future exposure.
  • Broadening vaccination strategies can maximize public health impact against HPV.